🔎 Trials Near Me

Akèy › Kansè lestomak › Texas

Etid klinik pou Kansè lestomak nan Texas

60 etid pou Kansè lestomak ap chèche patisipan nan sit nan Texas.

Vil nan Texas

Tèks ofisyèl etid la (Anglè)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • The Don and Sybil Harrington Cancer Center, Amarillo
  • UT MD Anderson Cancer Center, Houston
  • Audie L Murphy VA Hospital, San Antonio
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  • The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06760819

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

  • NEXT Oncology, Austin
  • UT Southwestern, Dallas
Ap rekriteFaz 1
Laj 19 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06586957

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • The University of Texas MD Anderson Cancer Center, Houston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06172478

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

  • Texas Oncology - Amarillo Cancer Center, Amarillo
  • Texas Oncology-Austin Central, Austin
  • Texas Oncology, Beaumont
  • ak 4 plis
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07221149

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

  • Research Site, Houston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06219941

Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

  • Baylor Scott & White Health, Dallas
  • MD Anderson Cancer Center, Houston
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07700979

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

  • NEXT Houston, Galveston
  • NEXT Oncology - PARENT, San Antonio
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07360314

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

  • NEXT Dallas, Irving
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07578571

IKS014 in Advanced Solid Tumors That Express HER2

  • START Dallas - Fort Worth, Fort Worth
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05872295

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

  • US Oncology Investigational Products Center (IPC), Irving
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07392892

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

  • Baylor, Scott and White Research Institute, Dallas
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06047379

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

  • Research Site, Houston
Ap rekriteFaz 2
Laj 18 a 130 · Tout sèks · Mizajou Sep 23, 2026 · NCT05489211

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • MD Anderson, Houston
  • NEXT Dallas, Irving
  • NEXT Oncology San Antonio, San Antonio
  • ak 1 plis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06128551

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

  • Texas Oncology - DFW (Sammons CC), Dallas
  • MD Anderson Cancer Center, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07114601

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

  • Texas Oncology - DFW (Sammons CC), Dallas
  • Baylor College of Medicine, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07213791

A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

  • The University of Texas MD Anderson Cancer Center, Houston
  • NEXT Oncology, San Antonio
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT07705334

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

  • Texas Oncology (Balcones) - SCRI, Austin
  • MD Anderson Cancer Center, Houston
  • START South Texas Accelerated Research Therapeutics, San Antonio
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT05267626

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

  • Start - Dfw, Fort Worth
  • Oncology Consultants, Houston
  • START - San Antonio, San Antonio
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06293898

A Phase 1/1b Study of IAM1363 in HER2 Cancers

  • NEXT Oncology - Austin, Austin
  • Mary Crowley Cancer Research, Dallas
  • MD Anderson Cancer Center - University of Texas, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06253871

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

  • Research Site, Dallas
  • Research Site, Dallas
  • Research Site, Houston
  • ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07431281

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

  • Mary Crowley Cancer Research, Dallas
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06750185

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

  • UT MD Anderson Cancer Center, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06364410

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

  • The University of Texas MD Anderson Cancer Center, Houston
  • South Texas Accelerated Research Therapeutics (START), LLC, San Antonio
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT07070232

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

  • NEXT Austin, Austin
  • NEXT San Antonio, San Antonio
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT07227168

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

  • Research Site, Houston
  • Research Site, San Antonio
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT07115043

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

  • MD Anderson Cancer Center, Houston
  • NEXT Dallas, Irving
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 13, 2026 · NCT07066657

A Study of MGC026 in Participants With Advanced Solid Tumors

  • The University of Texas MD Anderson Cancer Center, Houston
  • University of Texas Health Science Center at Houston, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT06242470

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  • The University of Texas, MD Anderson Cancer Center, Houston
  • UT Health Mays Cancer Center, San Antonio
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT05592626

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  • UT Southwestern Medical Center, Dallas
  • Texas Oncology, P.A. - Tyler, Tyler
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 10, 2026 · NCT06731478

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

  • Clinical Trial Site, San Antonio
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07749586

IDOV-Immune for Advanced Solid Tumors

  • MD Anderson Cancer Center, Houston
  • South Texas Accelerated Research Therapeutics, San Antonio
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06910657

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

  • Texas Oncology, Dallas
  • Oncology Consultants, Houston
  • Texas Oncology, Tyler
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 29, 2026 · NCT03526835

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  • The University of Texas Health Science Center at Tyler, Tyler
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 29, 2026 · NCT04198766

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

  • Investigative Site #129, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 23, 2026 · NCT06974110

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

  • University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
  • UT Southwestern Medical Center - Redbird, Dallas
  • Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital, Dallas
  • ak 8 plis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT05208762

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

  • The University of Texas MD Anderson Cancer Center, Houston
  • NEXT Dallas, Irving
  • South Texas Accelerated Research Therapeutics, LLC, San Antonio
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT06131840

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

  • Texas Oncology - Central South, Austin
  • START San Antonio, LLC., San Antonio
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 15, 2026 · NCT06657144

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

  • Texas Oncology - DFW, Dallas
  • MD Anderson Cancer Center, Houston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 10, 2026 · NCT06695845

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  • Oncology Consultants, PA, Houston
  • Oncology Consultants, PA., Houston
  • The University of Texas M.D. Anderson Cancer Center, Houston
  • ak 5 plis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 6, 2026 · NCT04389632

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.